The global women’s health care market size was valued at USD 23.09 billion in 2025 and is projected to grow from USD 26.32 billion in 2026 to USD 75.09 billion by 2034, registering a CAGR of 14% during the forecast period from 2026 to 2034. North America dominated the women’s health care market with a market share of 38.6% in 2025.
As per the WHO, the number of women age 60 and over will increase from about 336 million in 2000 to over 1 billion in 2050. Many of the biggest healthcare companies in the country, including Centene, Elevance Health, and CVS, are now led by women. Women have 25% of leadership positions in the global healthcare industry, according to the WHO, even though they only make up 10% of C-suite positions at Fortune 500 companies. These figures are hardly shocking, as women make up about 70% of the healthcare workforce. According to the National Osteoporosis Foundation, of the estimated 10 million Americans with osteoporosis, about eight million, or 80%, are women.
Women go through certain unique health care challenges and are more likely to be diagnosed with certain diseases than men. The leading causes of death among women are chronic diseases and conditions such as cardiovascular diseases (CVD), cancer, and diabetes. Therefore, there is a high demand for women’s healthcare.
Download a Free Sample To learn more about this report,
Growing Demand for Non-Hormonal and Personalized Treatments
The women’s health care market is shifting toward non-hormonal medicines, personalized care, and digital support across menopause, fertility, contraception, and gynecological disorders. Women increasingly seek treatments that match their age, symptoms, medical history, and lifestyle. This demand is encouraging pharmaceutical companies to develop targeted therapies with improved safety and convenient dosing. Menopause care is receiving particular attention as awareness of hot flashes, sleep problems, and long-term health effects improves. Bayer estimates that 1.2 billion women will be experiencing menopause by 2030, with approximately 47 million entering the transition annually, creating sustained demand for specialized care and education.
Rising Need for Contraception and Life-Stage Health Services
Demand for women’s health care is growing because of increasing awareness of contraception, fertility, menopause, osteoporosis, and reproductive disorders. Longer life expectancy is expanding the number of women requiring postmenopausal and bone-health treatments. At the same time, unmet reproductive health needs remain considerable. WHO estimates that 164 million women of reproductive age have an unmet need for contraception, highlighting substantial demand for affordable and accessible products. Greater screening, improved diagnosis of endometriosis and gynecological cancers, and growing acceptance of preventive care are also increasing treatment uptake. Government programs and employer health benefits are further improving access to women-focused consultations, medicines, diagnostics, and digital health services.
Safety Concerns, Access Restrictions, and Treatment Costs
The market is restrained by safety concerns surrounding hormonal therapies, contraceptive devices, and long-term drug use. Some treatments require careful patient selection because they may increase risks involving blood clots, cardiovascular events, or certain cancers. Regulatory reviews and post-market monitoring can therefore lengthen development timelines and raise compliance costs. High medicine prices, limited insurance coverage, social stigma, and shortages of trained gynecologists also restrict treatment adoption, particularly in lower-income communities. Policy changes affecting reproductive services create additional uncertainty for manufacturers and patients. These barriers can delay diagnosis, reduce prescription volumes, and prevent women from consistently using contraception, fertility treatments, menopause medicines, and preventive services.
Expanding Access to Modern Contraception and Menopause Care
Major opportunities exist in underserved contraception, fertility, maternal health, menopause, and gynecological care. WHO reported that 874 million women were using modern contraceptives in 2022 and projected that another 70 million could gain access by 2030. This creates room for manufacturers to introduce long-acting, hormone-free, affordable, and easier-to-use options. Digital consultations, home diagnostics, remote monitoring, and educational platforms can extend services to women who lack specialist care. Companies can also develop treatments for overlooked conditions such as endometriosis, polycystic ovary syndrome, and menopausal sleep disturbance. Partnerships with governments and community health providers can widen distribution while strengthening diagnosis, treatment adherence, and patient education.
A key challenge is the wide difference in women’s healthcare access between countries, income groups, and urban and rural populations. Weak health infrastructure, limited diagnostic capacity, medicine shortages, and insufficient numbers of skilled professionals delay essential treatment. WHO estimated that approximately 260,000 women died from pregnancy- or childbirth-related causes in 2023, with around 92% of these deaths occurring in low- and lower-middle-income countries. Research gaps also make product development difficult because several female-specific conditions remain underdiagnosed or poorly understood. Companies must generate diverse clinical evidence while managing cultural stigma, complex regulations, affordability pressures, and different healthcare delivery systems across international markets.
Hormonal therapy dominated the women’s health care market with a 61.7% share and a value of USD 14.25 billion in 2025. The segment is projected to expand at a CAGR of 5.46% during the forecast period. Its strong position is supported by the widespread use of hormonal products for contraception, menopause management, menstrual disorders, fertility treatment, and conditions such as endometriosis and polycystic ovary syndrome. Established clinical use, broad product availability, and continuous improvements in formulations and delivery methods further support demand. Growing awareness of reproductive health and improved access to specialist care are also strengthening this segment.
Non-hormonal therapy is gaining attention among women who cannot use hormone-based medicines or prefer treatment options with different safety profiles. These therapies address areas such as menopausal symptoms, osteoporosis, urinary conditions, sexual health, and certain gynecological disorders without directly changing hormone levels. Demand is being supported by concerns about the possible side effects of long-term hormonal treatment and the need for more personalized care. Pharmaceutical companies are developing targeted medicines with improved effectiveness and convenient dosing. Better patient education and rising interest in individualized treatment plans are expected to strengthen the adoption of non-hormonal products.
Request Customizationto receive a tailored report.
Oncology is the fastest-growing application segment, accounting for a 17.3% market share and a value of USD 3.99 billion in 2025. It is anticipated to grow at a CAGR of 6.64% during the forecast period. Growth is being driven by the rising detection of breast, ovarian, cervical, uterine, and endometrial cancers among women. Expanding screening programs, improved diagnostic technologies, and greater awareness of early cancer symptoms are increasing treatment demand. The development of targeted therapies, immunotherapies, and personalized medicines is also improving clinical outcomes. Public health campaigns and broader access to oncology services further support the segment’s strong growth prospects.
Hormonal treatment remains widely used for contraception, menopause symptoms, menstrual irregularities, and hormone-related disorders. Gynecological disorder care is expanding as awareness of endometriosis, fibroids, and polycystic ovary syndrome improves. Pregnancy care benefits from increasing demand for prenatal monitoring, nutritional support, fertility assistance, and safer delivery services. Urinary health products address infections, incontinence, pelvic-floor weakness, and bladder disorders that commonly affect women across different life stages. Other applications include sexual wellness, preventive care, bone health, and general female-specific conditions. Together, these areas support broader demand for integrated services tailored to women’s changing healthcare needs.
Prolia held the leading position in the drug segment, capturing a 16.4% market share and generating USD 3.79 billion in 2025. The segment is expected to register a CAGR of 6.21% over the forecast period. Prolia is widely prescribed to reduce fracture risk in postmenopausal women with osteoporosis and in patients considered vulnerable to significant bone loss. Its market leadership is supported by the growing population of aging and postmenopausal women, greater use of bone-density testing, and improved awareness of osteoporosis-related complications. Convenient administration and established clinical effectiveness also support its adoption across hospitals, specialist centers, and outpatient settings.
Premarin and Vagifem are used in managing menopausal and vaginal symptoms, while Mirena, NuvaRing, Lo Loestrin Fe, and Yasmin serve important roles in contraception and menstrual management. Forteo supports the treatment of severe osteoporosis, whereas Lupron is prescribed for selected hormone-responsive conditions, including endometriosis and uterine fibroids. Makena has faced regulatory and commercial pressure, influencing its position within the wider drug category. Other medicines include emerging therapies and established products for reproductive, hormonal, and bone-related conditions. Competition across these treatments depends on clinical benefits, safety, affordability, delivery convenience, regulatory status, and patient preferences.
Research institutes represent the fastest-growing end-user segment, with a 10.6% market share and a value of USD 2.45 billion in 2025. The segment is projected to advance at a CAGR of 6.47% throughout the forecast period. Its growth is supported by increasing research into endometriosis, infertility, menopause, maternal health, gynecological cancers, and sex-specific treatment responses. Greater attention from governments, academic institutions, and pharmaceutical companies is encouraging clinical trials and biomarker studies focused on women. Research institutes also play an important role in developing targeted drugs, diagnostic technologies, and personalized care approaches, helping address long-standing evidence gaps in female-specific healthcare.
Hospitals and clinics remain central to women’s healthcare because they provide diagnosis, surgery, maternity care, oncology services, and emergency treatment within integrated clinical settings. Gynecology centers offer specialized care for reproductive disorders, fertility concerns, contraception, menstrual problems, and menopause management, often providing a more focused patient experience. Other end users include diagnostic facilities, community health organizations, home-care providers, and digital consultation platforms. These channels improve access to screening, follow-up care, education, and routine treatment. Expansion of outpatient services and telehealth is also helping women obtain timely support, particularly in areas with limited specialist availability.
Speak to an Analystto discuss market opportunities.
North America leads the women’s health care market with a 38.6% market share and a value of USD 8.91 billion. The region is projected to expand at a CAGR of 5.62%. Its dominant position is supported by advanced healthcare infrastructure, strong awareness of women-specific conditions, and broad access to gynecology, fertility, oncology, and menopause services. Demand is also encouraged by established screening practices, specialist availability, and the presence of major pharmaceutical and medical technology companies. Continued development of targeted medicines, diagnostic solutions, and personalized treatment approaches is expected to sustain regional market expansion.
The United States maintains a strong position in the women’s health care market due to its established pharmaceutical sector, advanced clinical research network, and wide availability of specialized medical services. Demand covers contraception, fertility treatment, pregnancy care, menopause management, osteoporosis, urinary health, and gynecological oncology. Growing public discussion of endometriosis, polycystic ovary syndrome, maternal care, and menopausal symptoms is encouraging more women to seek diagnosis and treatment. Hospitals, specialty clinics, research institutions, and digital health providers are expanding their offerings, while product innovation and personalized treatment approaches continue to influence competition and patient choice.
Canada’s women’s health care market benefits from a publicly supported healthcare system and increasing attention to reproductive, maternal, and preventive care. Healthcare providers are placing greater emphasis on early diagnosis, routine screening, contraception counseling, fertility services, and menopause support. Demand is also developing for treatments addressing osteoporosis, urinary disorders, endometriosis, and gynecological cancers. Academic institutions and research organizations contribute to the study of female-specific conditions and treatment outcomes. However, differences in specialist access between urban, rural, and remote communities create opportunities for telehealth, community-based services, and more coordinated patient referral systems.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific is the fastest-growing region in the women’s health care market, registering a CAGR of 6.71%. It holds a 23.8% market share and is valued at USD 5.5 billion. Regional growth is supported by improving healthcare access, expanding hospital networks, and increasing awareness of reproductive and preventive health services. Demand for fertility care, contraception, maternal health, cancer screening, and menopause treatment is rising as healthcare priorities evolve. Pharmaceutical manufacturers are also expanding their presence across developing and established markets. Greater use of digital consultations and specialized diagnostic services is helping address access gaps and support continued regional development.
Japan represents an important women’s health care market because of its advanced medical system and increasing need for services related to aging and menopause. Demand is developing for osteoporosis medicines, hormonal and non-hormonal menopause therapies, cancer screening, urinary health products, and fertility care. Healthcare providers are giving more attention to conditions that affect women throughout different stages of life, including menstrual disorders and gynecological diseases. Domestic and international companies compete through product quality, safety, and clinical differentiation. Improved workplace awareness and greater openness toward discussing female-specific health concerns are also helping women seek professional care earlier.
China’s women’s health care market is developing as healthcare infrastructure expands and awareness of reproductive and preventive care improves. Rising attention to fertility, pregnancy management, contraception, gynecological disorders, and cancer screening is strengthening demand for specialized products and services. Large hospitals continue to play a central role, while private clinics and digital platforms are making consultations more convenient in major cities. Pharmaceutical companies are increasing their focus on localized treatment needs, affordable medicines, and broader distribution. Unequal access between urban and less-developed areas remains a concern, creating opportunities for telemedicine, community screening, and improved referral networks.
Europe accounts for a 27.4% share of the women’s health care market and has a value of USD 6.33 billion. The region is forecast to grow at a CAGR of 5.31%. Market demand is supported by structured healthcare systems, established preventive programs, and increasing attention to reproductive health, menopause, osteoporosis, and gynecological diseases. Access to prescription medicines and specialist services encourages continued treatment adoption. Research partnerships between universities, healthcare institutions, and pharmaceutical companies also support innovation. Growing interest in non-hormonal therapies, patient-centered care, and earlier diagnosis is expected to create additional development opportunities across the region.
Germany’s women’s health care market is supported by a well-developed healthcare system, strong pharmaceutical manufacturing capabilities, and extensive access to specialist treatment. Women can obtain services across contraception, fertility, pregnancy care, menopause management, bone health, urinary conditions, and gynecological oncology. Research hospitals and life sciences companies contribute to the development and evaluation of new medicines and diagnostic technologies. Demand is increasingly influenced by patient preference for effective treatments with manageable safety profiles. Preventive examinations and physician-led care remain important, while digital tools are beginning to improve appointment access, education, treatment monitoring, and communication between patients and providers.
The United Kingdom is placing greater emphasis on improving women’s experiences across reproductive health, maternity services, menopause, menstrual disorders, and gynecological care. Public awareness campaigns and more open workplace discussions have increased recognition of conditions that were previously overlooked or normalized. Demand is growing for menopause support, contraception, fertility treatment, endometriosis diagnosis, and cancer screening. Public healthcare services remain central to treatment delivery, while private clinics, pharmacies, and digital platforms provide additional access routes. Waiting times and differences in local service availability create opportunities for better care coordination, remote consultations, community support, and earlier diagnostic pathways.
Latin America holds a 6.1% market share in the women’s health care market, with a value of USD 1.41 billion. The region is anticipated to grow at a CAGR of 5.48%. Demand is supported by improving awareness of contraception, maternal health, gynecological diseases, fertility care, and cancer screening. Public health systems remain important for broad access, while private providers serve patients seeking faster or more specialized treatment. Gaps between urban and rural services continue to affect timely diagnosis and treatment. Expanding telehealth, community programs, and affordable pharmaceutical distribution could improve access and strengthen regional market growth.
Brazil is a key contributor to the women’s health care market in Latin America because of its large healthcare network, established pharmaceutical industry, and growing demand for reproductive and preventive services. Public and private providers offer contraception, prenatal care, fertility support, gynecological treatment, oncology services, and menopause management. Awareness of breast and cervical health encourages screening, although access and follow-up quality can vary between locations. Domestic manufacturing supports medicine availability, while international companies expand access through partnerships and distribution networks. Digital consultations and community health programs offer practical ways to reach women outside major metropolitan healthcare centers.
The Middle East and Africa represents a 4.1% share of the women’s health care market and is valued at USD 0.95 billion. The region is expected to record a CAGR of 5.12%. Growth is supported by expanding healthcare infrastructure, improving awareness of maternal and reproductive health, and increasing investment in specialist services. However, access differs widely across countries and between urban and rural communities. Demand is developing for contraception, fertility services, pregnancy care, cancer screening, and gynecological treatment. Greater availability of trained professionals, affordable medicines, and community-based services will remain important for regional market development.
The United Arab Emirates is developing as a specialized center for women’s health services within the Middle East. Modern hospitals and private clinics provide fertility treatment, maternity care, gynecology, cancer screening, menopause support, and preventive consultations. Medical tourism and the presence of international healthcare providers encourage investment in advanced diagnostic and treatment capabilities. Patients increasingly seek convenient, private, and personalized care supported by experienced specialists. Government attention to healthcare quality and digital transformation is also improving service delivery. Opportunities remain for culturally sensitive education, early screening programs, telehealth, and coordinated long-term care for women across different life stages.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Medical Packaging Market Size, Share, Growth, Analysis, 2034
High Potency API Contract Manufacturing Market Size, Share, Growth, 2034
Healthcare Finance Solutions Market Size, Share, Growth, 2034
Weight Loss Services Market Size, Share, Growth, Analysis, 2034
Product Design and Development Services Market Size, Share, 2034
Pediatric Clinical Trials Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com